← All stocks

TuHURA Biosciences, Inc./NV

HURA Net buying
CIK 0001498382 #4156 in the set updated 22 Sep 2026
Bought (120 mo)
$346.28K
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$346.28K
+$346.28K against sales at will

By person

13 insiders · 26 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Zarrabian Saiid
Head of Strategic Partnerships
$81.37K (4)
+$81.37K
61,400
$28.80K
Bell John K
Director
$76.15K (5)
+$76.15K
355,139
$166.56K
+37.8%
Praill Anthony Scott
Chief Financial Officer
$69.29K (4)
+$69.29K
277,273
$130.04K
BACHA JEFFREY
Director
$68.94K (6)
+$68.94K
64,049
$30.04K
+85.0%
Hoffman Robert E.
Director
$25.80K (1)
+$25.80K
68,902
$32.32K
Mohr Erich
Director
$15.00K (1)
+$15.00K
8,222
$3.86K
+2,190%
Cranston Lynda Sarah
Director
$7.50K (1)
+$7.50K
5,446
$2.55K
+111.6%
Johnson Laura L.
Director
$2.23K (1)
+$2.23K
3,000
$1.41K
Liatos John
SVP, Business Development
(1)
$0.00
196,750
$92.28K
Murphy Keith
Director
(1)
$0.00
181,010
$84.89K
Bianco James A.
Chief Executive Officer
2,173,307
$1.02M
Brown Dennis M
Chief Scientific Officer
944,398
$442.92K
+18.3%
TOTH ROBERT JOSEPH JR
Director
1,566
$734.45
+335.0%

No percentages here. This company's share count has moved by a factor of 1,274.3 over the window, from 43,680,397 to 55,660,578,000 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Hoffman Robert E.
15 Feb 2022
President and CEO
Buy
55,000
$0.47
$25.80K
Praill Anthony Scott
8 Dec 2021
Chief Financial Officer
Buy
28,700
$0.68
$19.43K
Zarrabian Saiid
7 Dec 2021
Head of Strategic Partnerships
Buy
38,109
$0.64
$24.30K
Zarrabian Saiid
6 Dec 2021
Head of Strategic Partnerships
Buy
11,891
$0.59
$7.02K
Johnson Laura L.
22 Nov 2021
Director
Buy
3,000
$0.74
$2.23K
Murphy Keith
19 Aug 2020
Director
Buy
181,010
no price
Liatos John
19 Aug 2020
SVP, Business Development
Buy
196,750
no price
Bell John K
13 Sep 2019
Director
Buy
35,000
$0.68
$23.74K
Bell John K
16 Nov 2017
Director
Buy indirect
18,129
$0.81
$14.68K
Bell John K
15 Nov 2017
Director
Buy indirect
1,871
$0.81
$1.52K
Zarrabian Saiid
14 Nov 2017
Interim CEO
Buy indirect
5,900
$0.84
$4.96K
Zarrabian Saiid
14 Nov 2017
Interim CEO
Buy
55,000
$0.82
$45.10K
BACHA JEFFREY
6 Oct 2017
CEO
Buy
2,450
$0.88
$2.16K
BACHA JEFFREY
6 Oct 2017
CEO
Buy
7,550
$0.87
$6.57K
Praill Anthony Scott
5 Oct 2017
Chief Financial Officer
Buy
17,500
$0.85
$14.91K
BACHA JEFFREY
26 Jun 2017
CEO
Buy
6,700
$3.60
$24.12K
Bell John K
26 Jun 2017
Director
Buy indirect
4,167
$3.60
$15.00K
Cranston Lynda Sarah
26 Jun 2017
Director
Buy indirect
2,083
$3.60
$7.50K
Mohr Erich
26 Jun 2017
Director
Buy
4,167
$3.60
$15.00K
Praill Anthony Scott
26 Jun 2017
Chief Financial Officer
Buy
4,167
$3.60
$15.00K
BACHA JEFFREY
6 Jun 2017
CEO
Buy
5,000
$2.12
$10.60K
Praill Anthony Scott
6 Jun 2017
Chief Financial Officer
Buy
9,500
$2.10
$19.95K
Bell John K
6 Jun 2017
Director
Buy indirect
10,000
$2.12
$21.20K
BACHA JEFFREY
5 May 2017
Chief Executive Officer
Buy
2,500
$2.20
$5.50K
BACHA JEFFREY
1 Feb 2017
CEO
Buy
4,000
$5.00
$20.00K
Brown Dennis M
31 Jan 2017
Chief Scientific Officer
Exercised, kept indirect
125,000
$1.54
$192.08K

What was left out

Form 4 filings counted 217
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 2
Shares from compensation/vesting 3,827,285
History held since 4 Oct 2016